Saposin B deficiency as a cause of adult-onset metachromatic leukodystrophy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 24, 2019
- Accepted in final form May 16, 2019
- First Published July 9, 2019.
Article Versions
- Previous version (July 9, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Silvia Fenu, MD*,
- Barbara Castellotti, PhD*,
- Laura Farina, MD,
- Tiziana Cavallaro, MD,
- Daniela Di Bella, MD, PhD,
- Chiara Benzoni, MD,
- Cinzia Gellera, PhD,
- Davide Pareyson, MD,
- Franco Taroni, MD and
- Ettore Salsano, MD
- Silvia Fenu, MD*,
NONE
NONE
1. Alnylam Pharmaceuticals: funding for travel to clinical research related meetings
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Barbara Castellotti, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laura Farina, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tiziana Cavallaro, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Daniela Di Bella, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Chiara Benzoni, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cinzia Gellera, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Davide Pareyson, MD,
1) Commercial entity: Member of the Scientific Advisory Board of Inflectis 2) Commercial entity: participated in Scientific Advisory Meetings of Alnylam 3) Commercial entity: participated in Scientific Advisory Meetings of Akcea
NONE
NONE
Neurological Sciences, member of the advisory board (2006-....) Journal of Neuromuscular Disorders, member of the editorial board (2014-....) Neurology Genetics, member of the editorial board (2017-....)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) LAM Therapeutics (donation for research activity) 2) Acceleron (donation for research activity)
NONE
NONE
1) Telethon-UILDM Italy (GUP15009; GUP 15010) 2) AFM-Telethon (#20667; #20821) 3) Charcot-Marie-Tooth Association (CMTA)
NONE
NONE
NONE
NONE
NONE
NONE
- Franco Taroni, MD and
Diaceutics Ltd/Bluebird Bio (Commercial): member of the italian scientific advisory board for adrenoleukodystrophy Associazione Italiana per la lotta alle Sindromi Atassiche (AISA) (non-profit patient association): member of the scientific advisory board
NONE
NONE
Neurological Sciences, Associate Editor, 2011-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Italian Ministry of Health grant, RF-2018-12367768, PI, 2019-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ettore Salsano, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Minoryx Therapeutics, S.L.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Unit of Rare Neurodegenerative and Neurometabolic Diseases (S.F., C.B., D.P., E.S.), Unit of Medical Genetics and Neurogenetics (B.C., D.D.B., C.G., F.T.), and Unit of Neuroradiology (L.F.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; Department of Neurology (T.C.), Azienda Ospedaliera Universitaria Integrata, University Hospital G.B. Rossi, Verona; and University of Milano-Bicocca (E.S.), Monza, Italy.
- Correspondence
Dr. Salsano ettore.salsano{at}istituto-besta.it
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.